Plain-language summary
======================

Chronic infection with hepatitis C virus (HCV) can cause liver cirrhosis in 5%--20% of patients. With cirrhosis, the risk of liver cancer and complications increases dramatically; however, successful antiviral treatment of chronic hepatitis C (CHC) reduces this risk. Little is known about the risk of liver cancer, complications, and death in patients with CHC and cirrhosis in Denmark. Therefore, this study aimed to estimate the incidence of liver cancer, liver complications, and liver-related death and how these were affected by successful antiviral treatment in patients with CHC and cirrhosis in Denmark. We performed an observational cohort study of nationwide data, and found that among patients with CHC and cirrhosis, HCV genotype 3 and alcohol overuse were associated with development of liver cancer, whereas diabetes mellitus was associated with development of liver complications. Curing CHC significantly reduced the rate of liver cancer and complications, as well as the rate of death. There is an urgent need to cure patients with CHC and cirrhosis, especially those with HCV genotype 3, and special attention needs to be given to patients with diabetes mellitus or alcohol overuse.

Introduction
============

Chronic infection with hepatitis C virus (HCV) is a disease of global importance with a large burden of morbidity and mortality.[@b1-clep-9-501]--[@b6-clep-9-501] For 5%--20% of chronic hepatitis C (CHC) patients, the disease will progress to liver cirrhosis[@b7-clep-9-501] associated with complications, such as liver decompensation, hepatocellular carcinoma (HCC), and increased mortality.[@b8-clep-9-501] The commonest causes of death among patients with CHC and cirrhosis are liver-related, particularly HCC.[@b8-clep-9-501],[@b9-clep-9-501] Several prognostic factors, such as diabetes mellitus, male sex, alcohol abuse, and HCV genotype 3, are thought to be associated with the development of HCC, decompensation, and mortality.[@b10-clep-9-501]--[@b14-clep-9-501]

Absence of HCV RNA 24 weeks after end of treatment (EOT~24~) is considered a cure for CHC, and is termed sustained virologic response (SVR).[@b15-clep-9-501] Patients with CHC and cirrhosis have previously been difficult to cure; however, achieving a cure for CHC has been shown to be associated with decreased morbidity and mortality.[@b10-clep-9-501],[@b12-clep-9-501] With the introduction of new, very effective antiviral drugs that cure CHC in nearly all treated patients,[@b16-clep-9-501] large cohorts of patients with CHC and cirrhosis who fail treatment in comparison with patients with SVR will be difficult to assemble.

Moreover, our knowledge of liver-related morbidity and mortality and how SVR affects these among patients with CHC and cirrhosis on a nationwide scale is limited. Most previous studies of HCC, decompensation, and liver-related mortality in CHC patients with cirrhosis have been single- or few-center studies, and included fairly selected cohorts from tertiary centers.[@b5-clep-9-501],[@b8-clep-9-501],[@b10-clep-9-501],[@b12-clep-9-501],[@b13-clep-9-501]

The aims of this nationwide cohort study were to estimate liver-related morbidity and mortality among patients with CHC and cirrhosis in Denmark with and without antiviral treatment, and to estimate liver-related morbidity and mortality associated with SVR in a relatively large cohort of treated CHC patients with cirrhosis. Furthermore, we aimed to estimate the rates of HCC and decompensation associated with certain prognostic factors.

Materials and methods
=====================

This observational cohort study used prospectively collected data. The Danish health-care system is publicly funded and provides health-care services free of charge to the individual. Patients were identified in the Danish Database for Hepatitis B and C (DANHEP). DANHEP is a nationwide database with ongoing enrolment established January 1, 2002.[@b17-clep-9-501] It contains demographic, clinical, liver-biopsy, laboratory, and treatment data, and transient-elastography measurements on patients seen with CHC and/or CHB in any of the specialized outpatient clinics responsible for CHC patients in Denmark after January 1, 2002. Cross-linkage between nationwide registries is possible due to the unique 10-digit personal identification number[@b18-clep-9-501] given to all residents in Denmark and registered in the Danish civil registration system, along with date of birth, sex, vital and migration status, and address. All hospital-admission dates and diagnoses are registered in the Danish national patient registry (NPR),[@b19-clep-9-501] histopathologic diagnoses are registered in the national Danish pathology database (Patobank),[@b20-clep-9-501] causes of death are registered in the Danish registry of causes of death,[@b21-clep-9-501] and cancer diagnoses are registered in the Danish cancer registry.[@b22-clep-9-501] Further information about the Danish registry of causes of death is provided in the Supplementary material, and the remaining registries are described in more detail elsewhere.[@b23-clep-9-501]

Patient cohort
--------------

Eligible patients were registered in DANHEP and fulfilled the following criteria: a positive HCV RNA test, cirrhosis and enrolment in DANHEP before December 31, 2013, ≥18 years of age, and a valid personal identification number and address in Denmark. All ICD and systematized nomenclature of medicine (SNOMED)[@b24-clep-9-501] codes used in the definitions of inclusion and exclusion criteria, outcomes, and covariates are provided in the Supplementary material. To avoid reverse causation and inclusion of prevalent cases of decompensation and HCC, the first 6 months of observation were excluded. Baseline was thus defined as 6 months (183 days) after the first date of a diagnosis of cirrhosis and enrolment in DANHEP, whichever occurred last, and could not precede January 1, 2002. Cirrhosis was defined as: liver biopsy (Metavir fibrosis score of F4),[@b25-clep-9-501] transient elastography (FibroScan; Echosens, Paris, France) median elasticity ≥17 kPa[@b26-clep-9-501],[@b27-clep-9-501] (10 or more valid measurements and an interquartile range ≤30% of median elasticity),[@b28-clep-9-501] or clinical cirrhosis (cirrhosis registered in NPR, ascites, hepatic encephalopathy, esophageal varices, esophageal variceal hemorrhage, spontaneous bacterial peritonitis). Patients were excluded if they had CHB, HIV infection, autoimmune hepatitis, or hemochromatosis at baseline.

Definition of outcomes and covariates
-------------------------------------

The two primary outcomes in the separate analyses of liver-related morbidity were HCC and decompensation. We defined HCC as a diagnosis registered in Patobank, the Danish registry of causes of death, the Danish cancer registry, or the NPR. Decompensated liver cirrhosis was defined as a diagnosis registered in the NPR, the Danish registry of causes of death, and/or DANHEP of ascites, esophageal variceal hemorrhage, hepatic encephalopathy, or spontaneous bacterial peritonitis.

In mortality analyses, the primary outcome was liver-related and all-cause mortality. All-cause mortality was defined as death due to any cause with a date of death registered in the Danish civil registration system, which was updated throughout the study period. Liver-related mortality was based on the underlying cause of death registered on the death certificate and divided into liver-related and liver-unrelated. Because the Danish registry of causes of death was only updated through December 2012 at the time of data extraction, analyses of liver-related mortality were limited to before December 31, 2012.

Antiviral treatment was registered in DANHEP and defined as reception of at least one dose of antiviral therapy. Based on information registered in DANHEP, successful treatment was defined as the absence of HCV RNA (SVR) at EOT~24~. Only patients who were alive and had negative HCV RNA samples at ≥EOT~24~ were categorized as having SVR. Non-SVR was defined as a treatment with known treatment response that did not result in SVR. Reinfection after SVR was defined as at least one positive HCV RNA after a period with undetectable HCV RNA after the EOT~24~ date.

Comorbidity was assessed by a time-updated, cumulative Charlson comorbidity index (CCI)[@b29-clep-9-501] score calculated based on ICD codes assigned to hospital contacts registered in the NPR (ICD codes modified by Quan et al[@b30-clep-9-501] are provided in the Supplementary material). Originally, the CCI score was developed to predict short-term, in-hospital mortality, but has subsequently been shown to predict long-term mortality.[@b31-clep-9-501] Liver disease, HCC, and HIV diagnoses were excluded from the CCI score. Orthotopic liver transplantation (LTx) was defined as an LTx procedure registered in the NPR. Diabetes mellitus was based on ICD codes registered in the NPR. Intravenous drug use (IDU; ever) was defined as having an IDU-related diagnosis registered in the NPR prior to the end of follow-up, self-reported IDU, or IDU as route of HCV transmission registered in DANHEP. Alcohol overuse was defined as any of the following prior to the end of follow-up: alcohol abuse-related diagnosis in NPR, a liver biopsy with a histopathologic diagnosis of alcoholic hepatitis or alcoholic cirrhosis, or self-reported daily alcohol consumption of \>36 g alcohol for men and \>24 g alcohol for women[@b32-clep-9-501] registered in DANHEP. Psychiatric disease was defined as a diagnosis of psychiatric disease registered in the NPR.

Statistical analysis
--------------------

Patient characteristics were compared between patient groups with Mann--Whitney *U* test, *χ*^2^ test, or *χ*^2^ test with Monte Carlo simulations using 10,000 samples. All rates and rate ratios were calculated using Poisson regression, where time at risk and number of events in different strata were calculated using the stratify macro.[@b33-clep-9-501]

Patients were followed from baseline until the primary outcome, exit for other reasons, or end of the study period, whichever occurred first. The study ended on December 31, 2013 except for liver-related mortality, where the last day of observation was December 31, 2012. When estimating rates in addition to reaching the end of the study period, infection with HIV, CHB, autoimmune hepatitis, or hemochromatosis led to censoring. Patients with prevalent cases of the primary outcome or LTx at baseline were excluded from morbidity analyses. A diagnosis of HCC before decompensation when decompensation was the primary outcome did not lead to the end of follow-up and vice versa. Cumulative-incidence functions of liver-related morbidity in all patients were calculated with death, coinfection with HIV or HBV, autoimmune hepatitis, hemochromatosis, and LTx as competing risks. Incidence rate ratios (IRRs) of HCC and decompensation were calculated to estimate the rates associated with predefined prognostic factors (sex, diabetes, alcohol overuse, and HCV genotype). In all Poisson regression analyses, CCI score (0, 1, 2, 3, 4, 5, ≥6), LTx, diabetes, psychiatric disease, HCC, and decompensation were introduced as time-dependent categorical covariates, whereas sex, alcohol overuse, IDU, and genotype (1, 2, 3, 4--6, multiple genotypes) were introduced as baseline categorical covariates. Age (\<40, 40--44,45--49, 50--54, 55--59, 60--64, 65--69, 70--74, 75--79, 80--84, 85--89, and ≥90 years) was used as a continuous, time-dependent covariate after testing for log linearity or as a categorical variable. In cases of insufficient events, appropriate covariate strata were combined to ensure events in all strata.

In estimates of rates of HCC, decompensation and mortality when comparing patients with SVR vs non-SVR time at risk were calculated from the first EOT~24~ date with known treatment response or baseline, whichever occurred last, until the primary outcome or end of follow-up. In addition to the reasons mentioned previously, patients were censored at reinfection. SVR was introduced as a time-dependent covariate, and the clock-reset approach was applied. Cumulative-incidence functions in SVR, non-SVR, and untreated patients treated death, LTx, SVR, treatment, coinfection with HIV or HBV, and other liver diseases as competing events. Untreated patients were followed from baseline until initiation of event, treatment, or end of follow-up. All statistical tests were two-sided with *a*=0.05. Data handling and statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, USA), except for cumulative-incidence functions and figures, where R (version 3.2.2)[@b34-clep-9-501] was used.

Ethics
------

This study was approved by the Danish Data Protection Agency (2013-41-2323) in accordance with Danish law.

Results
=======

Data were extracted from nationwide registries on 5,779 patients with positive HCV RNA. Of these, 1,306 patients had cirrhosis, and after the exclusion of 268 patients, 1,038 patients were eventually included (inclusion and exclusion of patients can be seen in [Figure S1](#SD1-clep-9-501){ref-type="supplementary-material"}). One patient (0.1%) was lost to follow-up with unknown address and vital status in the Danish civil registration system. Baseline characteristics of all patients, untreated and treated, are shown in [Table 1](#t1-clep-9-501){ref-type="table"}. Before the end of follow-up, 537 (52%) patients had initiated antiviral treatment, of whom 519 patients reached an EOT~24~ date at least once. The majority of treatment courses with a known treatment outcome consisted of a backbone of IFN (with or without Ribavirin).[@b15-clep-9-501] Only 45 (7%) patients were treated with polyethylene glycolated IFN combined with Ribavirin and a direct-acting antiviral (DAA) drug. Two patients were treated with Ribavirin monotherapy and failed to achieve SVR. Overall, 233 patients achieved SVR (45%), 276 patients achieved non-SVR (53%) at least once, and 10 patients had unknown treatment response (2%). A total of 27 patients achieved SVR~24~ after initially failing therapy. Three patients were reinfected and did not achieve a second SVR~24~. Characteristics of patients at their first EOT~24~ are listed in [Table S1](#SD2-clep-9-501){ref-type="supplementary-material"}.

Patients were followed for a median of 3.8 (range 0.01--12) and 4,909 years total. After the exclusion of patients with prevalent cases of HCC and/or LTx at baseline, among 989 patients at risk of HCC, 115 patients were diagnosed with HCC during follow-up. Similarly among 811 patients at risk of decompensation, 153 decompensated during followup. Of 1,038 patients included, 360 eventually died during follow-up. Of 299 deaths prior to December 31, 2012, 186 (62%) died of liver-related causes. The cumulative-incidence functions of liver-related morbidity are shown in [Figure 1](#f1-clep-9-501){ref-type="fig"}. Liver-related morbidity IRs and mortality rates (MRs) for all patients and for SVR, non-SVR, and untreated patients are shown in [Table 2](#t2-clep-9-501){ref-type="table"}. Adjusted liver-related morbidity IRRs are shown in [Table 3](#t3-clep-9-501){ref-type="table"} for all patients. In adjusted analyses, alcohol overuse was associated with increased rates of both HCC and decompensation among patients at risk, and compared to patients with genotype 1 or 2, genotype 3 was associated with an increased rate of HCC. In contrast, male sex and diabetes were not significantly associated with HCC. Genotype was not associated with decompensation, but diabetes was associated with an IRR of 1.65 for decompensation after adjusting for confounding.

Median and total follow-up years were 4.8 (range 0.04--12) and 1,197 after SVR and 3.8 (range 0.04--12) and 1,444 after non-SVR. Cumulative-incidence functions of liver-related morbidity for SVR, non-SVR, and untreated patients are shown in [Figures 2](#f2-clep-9-501){ref-type="fig"} and [3](#f3-clep-9-501){ref-type="fig"}. Of the 226 patients who achieved SVR and were at risk of HCC, 10 developed HCC maximum 6.1 years after SVR~24~. In contrast, of 289 patients at risk after non-SVR, 47 were diagnosed with HCC. After non-SVR, 56 of 266 patients at risk decompensated, whereas only 11 of 211 patients decompensated after SVR. One patient with SVR and 11 with non-SVR received LTx. Adjusted liver-related morbidity IRRs and MRRs for SVR vs non-SVR and untreated patients are presented in [Table 4](#t4-clep-9-501){ref-type="table"}. Cumulative incidences for 1-, 5-, and 10-year liver-related morbidity with death and LTx as competing risks are presented in [Table S2](#SD3-clep-9-501){ref-type="supplementary-material"}. Achieving SVR was associated with a reduced rate of HCC, even after adjusting for sex, age, alcohol overuse, genotype, and diabetes. The rate of decompensation was also reduced substantially in the presence of SVR, and of the 11 patients who decompensated after SVR, seven had a history of alcohol overuse. Adjusted all-cause and liver-related MRs were reduced by 34% and 40% with SVR, respectively, when taking confounding into account.

Discussion
==========

This nationwide cohort study based on prospectively collected data adds to our knowledge of liver-related morbidity and mortality among CHC patients with cirrhosis in a real-life cohort. We found major differences between untreated and treated patients with regard to baseline characteristics associated with mortality. A history of alcohol overuse and genotype 3 were associated with increased rates of HCC, whereas diabetes increased the rate of decompensation, as did alcohol overuse. Achieving SVR was associated with markedly reduced rates of liver-related morbidity and mortality after adjustment for confounding. However, a history of alcohol overuse was associated with diagnoses of HCC and decompensation after SVR.

Patients who did not initiate treatment differed from treated patients with respect to several baseline characteristics, such as comorbidity, decompensated cirrhosis, HCC, and a history of alcohol overuse or IDU. These differences were reflected in the high all-cause mortality among untreated patients, even compared to patients with non-SVR~24~. These differences are probably primarily a result of the selection of healthier patients for antiviral treatment, in part due to contraindications to polyethylene glycol--IFN-based therapy[@b15-clep-9-501] and other possible factors, such as continuous links to care.

We found IRs of HCC ranging from 0.85 after SVR to 3.53 after non-SVR per 100 person-years (PYs). Some studies have reported an increased rate of HCC associated with HCV genotype 3 independently of alcohol overuse, obesity, and diabetes.[@b12-clep-9-501],[@b35-clep-9-501] The confirmed increased rate of HCC associated with genotype 3 observed in our adjusted analyses did not take SVR into account. However, given the fact that both genotypes 2 and 3 were associated with higher chances of SVR[@b36-clep-9-501] in the era of IFN and Ribavirin compared with genotype 1, we find it unlikely that differences in SVR rates among patients with different genotypes should explain the observed increased rate of HCC associated with genotype 3. We found no statistically significant association between sex or diabetes and HCC, as has been described elsewhere,[@b10-clep-9-501],[@b11-clep-9-501],[@b13-clep-9-501],[@b37-clep-9-501],[@b38-clep-9-501] whereas diabetes did increase the rate of decompensation. Previously, it has been suggested that diabetes and genotype 3 are associated with fibrosis progression[@b39-clep-9-501]--[@b41-clep-9-501] and complications in cirrhotic patients.[@b14-clep-9-501] The complex carcinogenic biological mechanisms involved in the development of HCC in the presence of diabetes and HCV genotype 3 are not fully understood. However, steatosis is thought to play a key role,[@b42-clep-9-501] and diabetes and HCV show signs of a synergistic effect in the formation of HCC.[@b13-clep-9-501],[@b43-clep-9-501] Apart from being associated with obesity and diabetes, steatosis is also generally accepted to be associated with HCV genotype 3,[@b44-clep-9-501] which may partly explain the increased risk of HCC. Nonetheless, the absence of information on steatosis and steatohepatitis in this study precludes any further conclusions on this matter. Alcohol overuse is a well-known risk factor,[@b38-clep-9-501] and was also strongly associated with HCC in this study. We did not observe an association between male sex and HCC, as demonstrated elsewhere,[@b8-clep-9-501],[@b10-clep-9-501],[@b12-clep-9-501],[@b13-clep-9-501],[@b45-clep-9-501] and we have no good explanation for this (crude rate male vs female 1.18 \[95% CI 0.83--1.68\] vs adjusted rate 1.21 \[95% CI 0.86--1.69\] per 100 PYs). While it was unclear which covariates were included in the final multivariate Cox regression models performed in previously published studies,[@b8-clep-9-501],[@b10-clep-9-501],[@b12-clep-9-501],[@b13-clep-9-501],[@b45-clep-9-501] we find it unlikely that the lack of an association in our study is the result of confounding. It may simply be due to chance. Death would be considered a competing event with HCC, and the MR was higher among men than women (adjusted MRR 1.39 \[95% CI 1.07--1.8\]); however, a rate is independent of competing events. Similarly, we found no association between diabetes and HCC, which has been demonstrated consistently,[@b11-clep-9-501]--[@b13-clep-9-501],[@b38-clep-9-501] though mainly after SVR. In our study, diabetes was based entirely on the NPR. Misclassification in cases of diabetes not registered in the hospital registry may have occurred, which would bias the results toward the null. The positive predictive value of a diagnosis of diabetes in the NPR has been demonstrated to be good.[@b46-clep-9-501],[@b47-clep-9-501] However, the prevalence of diabetes of 12% at baseline in our cohort was at the lower end compared to the 12%--24% in other cohorts,[@b11-clep-9-501]--[@b13-clep-9-501],[@b48-clep-9-501] which could suggest that we have underestimated the true diabetes prevalence. Alternatively, since other studies have mainly been performed in single or few tertiary centers, it may also be that the association between diabetes and HCC demonstrated by some could be the result of selection bias. Because diabetes was introduced as a time-dependent variable in our regression analyses, one could argue that this could lead to reverse causation of diabetes and HCC, if diabetes was more likely to be diagnosed in patients with yet-undiagnosed HCC. However, this would lead to a stronger association between diabetes and HCC, which was not the case in our study. Furthermore, the median time from diabetes to HCC was 4.6 years and 3.9 years from diabetes to decompensation, which makes reverse causation unlikely. Interestingly, in our cohort diabetes was associated with HCC in an unadjusted analysis and when adjusting for everything but age (data not shown). Patients with diabetes were also slightly older than patients without diabetes, and the rate of HCC increased significantly with age. Therefore, at least in this study, an association between diabetes and HCC was confounded by age. The HCC IR of 0.85/100 PYs after SVR observed in our cohort is consistent with the HCC IRs of 0.55--1.39/100 PYs described by others after SVR.[@b10-clep-9-501],[@b12-clep-9-501],[@b38-clep-9-501],[@b49-clep-9-501],[@b50-clep-9-501] The lowest HCC IR after SVR was reported in a study by van der Meer et al (0.55/100 \[95% CI 0.14--0.96\] PYs),[@b12-clep-9-501] which had a long median follow-up (8.4 years), but included 46% patients with advanced fibrosis, slightly younger patients (median age 48 years), and only patients with compensated cirrhosis. The highest HCC IR estimate reported of 1.39/100 PYs was found in a large cohort consisting of 95% males with a relatively high prevalence of diabetes and alcohol abuse,[@b38-clep-9-501] all risk factors previously described to be associated with HCC.[@b10-clep-9-501],[@b12-clep-9-501],[@b13-clep-9-501],[@b38-clep-9-501] Our results on the continuously elevated rate of HCC after non-SVR are well within the estimates reported in other cohorts of 1.44--5.85/100 PYs.[@b10-clep-9-501],[@b12-clep-9-501],[@b49-clep-9-501]--[@b51-clep-9-501] We were able to confirm the reduced rate of HCC in cirrhotic CHC patients associated with SVR reported previously.[@b10-clep-9-501],[@b12-clep-9-501],[@b49-clep-9-501],[@b50-clep-9-501] These results underscore the benefits associated with a cure for CHC in cirrhotic patients. Despite small differences in the definition of liver complications applied here and elsewhere, we also found a markedly reduced rate of decompensation associated with SVR, in line with previous results.[@b10-clep-9-501],[@b12-clep-9-501],[@b49-clep-9-501],[@b50-clep-9-501] It is noteworthy that the annualized risk of HCC of 1.08% during the first 5 years after SVR found in our cohort is below the threshold of cost-effectiveness of 1.5%/year for HCC surveillance.[@b52-clep-9-501],[@b53-clep-9-501] However, the cutoff was estimated in the 1990s based on patients with multiple etiologies and exclusively cirrhosis Child--Pugh A. This was during in an era when CHC was difficult to cure, with presumably shorter life expectancies. At this point, the European Association for the Study of the Liver recommends continued HCC surveillance after SVR in cirrhotic patients.[@b16-clep-9-501] Further studies are needed to determine whether surveillance for HCC is cost-effective after SVR, and if so, for how long after SVR surveillance should be recommended.

The fact that adjusted all-cause and liver-related MRRs associated with SVR did not reach statistical significance in this study may have been due to underpowering when adjusting for confounding. We are confident that SVR was truly associated with reduced mortality in this real-life cohort, as has been demonstrated previously.[@b23-clep-9-501] With highly effective DAAs, even patients with advanced liver disease and comorbidities can undergo treatment and achieve very high SVR rates.[@b16-clep-9-501] Therefore, it will be of interest to follow CHC patients cured with IFN-free DAA regimens to study the long-term effects of eradicating HCV in patients with advanced liver disease, comorbidity, and/or substance abuse that would have precluded them from IFN and Ribavirin-based therapy.

The unique tradition for nationwide health registries and opportunity to cross-link between registries ensured complete follow-up in this cohort study of prospectively collected data. Unfortunately, only a fraction of the total number of patients with CHC in Denmark are aware of their CHC-status and attend specialized care,[@b54-clep-9-501] which limits the generalizability of our morbidity-rate and MR estimates, due to potential selection bias. For example, if only the sickest patients attend specialized care with symptoms of and complications due to CHC, we could have overestimated the rates of liver-related morbidity and mortality associated with CHC.

Reporting cancer diagnoses to the Danish cancer registry by physicians is mandatory, and since hospitals in Denmark are reimbursed based on admissions and procedures registered in the NPR, the number of HCC cases diagnosed in hospitals not registered in the cancer registry, Patobank, or NPR is likely to be low. A recent study from Sweden suggests that relying on a single registry could lead to substantial underestimation of primary liver cancers, possibly due to the noninvasive nature of HCC diagnosis.[@b55-clep-9-501] In our study, we extracted information from four different registries, which confers validity to our results. However, it is possible that we underestimated the number of HCC cases due to unrecognized HCC in deceased patients in the absence of diagnostic imaging or autopsy. Only two patients were diagnosed with HCC exclusively in the registry of causes of death. With regard to decompensation, it is likely that the registration of this complication is less rigorous than HCC, since we had to rely on only two registries, and thus it is possible that we underestimated the occurrence of decompensation.

Other limitations include the fact that we did not have information about smoking status, valid HCV RNA concentrations, body-mass index, nonalcoholic fatty-liver disease, nonalcoholic steatohepatitis, CHC disease duration, Child--Pugh or MELD (model for end-stage liver disease) score, systematic information about cirrhosis regression, quantification and duration of alcohol intake, or information about current alcohol overuse or IDU. These are all important potential confounding factors.

In conclusion, we found high rates of liver-related morbidity and mortality among patients with CHC and cirrhosis, in particular among untreated patients. Genotype 3 and alcohol overuse were associated with increased rates of HCC, and diabetes and alcohol overuse increased the rate of decompensation. Successful eradication of HCV was associated with substantially reduced rates of liver-related mortality, HCC, and liver decompensation when adjusting for confounding. There continues to be an urgent need to cure patients with CHC and cirrhosis before the development of complications, particularly in those with genotype 3. Special attention should be given to patients with a history of alcohol overuse in whom an elevated rate of HCC and decompensation remain after SVR.

Supplementary materials
=======================

Data sources
------------

Danish civil registration system, Danish Database for Hepatitis B and C (DANHEP), Danish national patient registry (NPR), national Danish pathology database (Patobank), and Danish cancer registry provided in supplementary material published previously.[@b56-clep-9-501]

The Danish register of causes of death (DAR) is a nationwide registry that contains information on nearly every death in Denmark since 1943. On each death certificate, a physician has registered one or more diagnoses considered to be the cause(s) of death, and coded with appropriate ICD-10 codes during this study period.[@b57-clep-9-501]

Definition of covariates
------------------------

Lists of ICD-8, ICD-10, and SNOMED codes used in the definition of inclusion and exclusion criteria, covariates, and causes of death are supplied in [Tables S1](#SD2-clep-9-501){ref-type="supplementary-material"}[](#SD3-clep-9-501){ref-type="supplementary-material"}[](#SD4-clep-9-501){ref-type="supplementary-material"}[](#SD5-clep-9-501){ref-type="supplementary-material"}--[S5](#SD6-clep-9-501){ref-type="supplementary-material"}.

###### 

Inclusion and exclusion of patients with CHC and cirrhosis.

**Abbreviations:** PIN, personal identification number; HCV, hepatitis C virus; CHC, chronic hepatitis C; CHB, chronic hepatitis B; TE, transient elastography; SVR, sustained virologic response; HCC, hepatocellular carcinoma.

###### 

Codes for assorted conditions

  Cirrhosis                                                                                 
  ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------
  National Danish pathology database (Patobank)                                             SNOMED: M49500, M49501, M49503, M49504, M49506, M49510, M49514, M49516, M49520, M49524, M49526, M49527, M49528, M49530, Æyyya4, ÆYYYA4
  National patient registry (NPR)                                                           ICD-10: K74.6
  Esophageal varices: ICD-8, 456.09, 456.00, 456.01; ICD-10, I85.X, I86.4                   
  Esophageal variceal hemorrhage: ICD-8, 456.01; ICD-10, I85.0                              
  Ascites: ICD-8, 785.39; ICD-10, R18, R18.9, KTJA10A, KTJA10B                              
  Hepatic encephalopathy/liver failure: ICD-8, 57300; ICD-10, K72, B19.0, G92.9, G93.4      
  Spontaneous bacterial peritonitis: ICD-10, K65.8I                                         
  Danish Database for Hepatitis B and C (DANHEP)                                            Esophageal varices, ascites, hepatic encephalopathy
  Registry of causes of death (DAR)                                                         Esophageal varices: ICD-10, I85.X, I86.4
  Esophageal variceal hemorrhage: ICD-10, I85.X, I86.4                                      
  Ascites: ICD-10, R18, R18.9                                                               
  Hepatic encephalopathy or liver failure: ICD-10, K72, B19.0, G92.9, G93.4                 
  Spontaneous bacterial peritonitis: ICD-10, K65.8I                                         
  Chronic hepatitis B                                                                       
  DANHEP                                                                                    A positive HBsAg
  HIV/AIDS                                                                                  
  DANHEP                                                                                    A positive HIV-antibody/antigen test
  NPR                                                                                       ICD-8, 07.983; ICD-10, B20.0--24.9
  Autoimmune hepatitis                                                                      
  NPR                                                                                       ICD-10, K75.4, K73.2
  Patobank                                                                                  SNOMED, S63580
  Hemochromatosis                                                                           
  NPR                                                                                       ICD-8, 273.29; ICD-10, E83.1A
  Patobank                                                                                  SNOMED, S11920
  Wilson's disease                                                                          
  NPR                                                                                       ICD-8, 273.39; ICD-10, E83.0B
  Patobank                                                                                  SNOMED, S87250
  Hepatocellular carcinoma                                                                  
  Danish cancer registry (CAR)                                                              ICD-10, C22.0, C22.9
  NPR                                                                                       ICD-10, C22.0, C22.9
  Patobank                                                                                  SNOMED, M81703, M81704, M81706, M81707, M81709
  DAR                                                                                       ICD-10, C22.0, C22.9
  Liver transplantation                                                                     
  NPR                                                                                       ICD-10, Z94.4, KJJC, KJJC00, KJJC10, KJJC20, KJJC96, DZ944, DT864, DT864A, DT864B
  History of alcohol abuse                                                                  
  DANHEP                                                                                    Self-reported alcohol consumption of more than 3 units of alcohol per day for men and 2 units per day for women
  NPR                                                                                       ICD-8, 291.00--291.99, 571.09, 571.10, 303.00--303.89, 303.91--303.99; ICD-10, K 70.0--70.9, F10.2--F10.9, G31.2
  Patobank                                                                                  SNOMED, S63590, M49660
  History of intravenous drug abuse                                                         
  DANHEP                                                                                    Self-reported intravenous drug use or route of transmission of HCV as intravenous drug use
  NPR                                                                                       ICD-8, 304.09--304.99; ICD-10, F11.0--F19.9, T40.0--T40.9
  Psychiatric disease                                                                       
  NPR                                                                                       ICD-8, 295.00--302.99, 305.00--315.99; ICD-10, F20.0--FF99.9
  Decompensated liver cirrhosis                                                             
  NPR                                                                                       Esophageal variceal hemorrhage: ICD-8, 456.01, ICD-10, I85.0
  Ascites: ICD-8, 785.39; ICD-10, R18, R18.9, KTJA10A, KTJA10B                              
  Hepatic encephalopathy or liver failure: ICD-8, 57300; ICD-10, K72, B19.0, G92.9, G93.4   
  Spontaneous bacterial peritonitis: ICD-10, K65.8I                                         
  DANHEP                                                                                    Esophageal varices, ascites, hepatic encephalopathy
  DAR                                                                                       Esophageal variceal hemorrhage: ICD-10, I85.X, I86.4
  Ascites: ICD-10, R18, R18.9                                                               
  Hepatic encephalopathy or liver failure: ICD-10, K72, B19.0, G92.9, G93.4                 
  Spontaneous bacterial peritonitis: ICD-10, K65.8I                                         

**Abbreviations:** SNOMED, systematized nomenclature of medicine; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; ICD-10, 10th revision of the International Statistical Classification of Diseases and Related Health Problems.

###### 

ICD codes used in definition of Charlson comorbidity index score

  Comorbid conditions[a](#tfn16-clep-9-501){ref-type="table-fn"}                       ICD-8                                                            ICD-10                                                                                                                                                                          Score
  ------------------------------------------------------------------------------------ ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  Myocardial infarction                                                                410                                                              I21.x, I22.x, I25.2                                                                                                                                                             1
  Congestive heart failure                                                             427.09, 427.10, 427.11,427.19, 428.99, 782.49                    I09.9, I11.0, I13.0, I13.2, I25.5, I42.0, I42.5--I42.9, I43.x, I50.x, P29.0                                                                                                     1
  Peripheral vascular disease                                                          440--445                                                         I70.x, I71.x, I73.1, I73.8, I73.9, I77.1, I79.0, I79.2, K55.1, K55.8, K55.9, Z95.8, Z95.9                                                                                       1
  Cerebrovascular disease                                                              430--438                                                         G45.x, G46.x, H34.0, I60.x--I69.x                                                                                                                                               1
  Dementia                                                                             290.09--290.19, 293.09                                           F00.x--F03.x, F05.1, G30.x, G31.1                                                                                                                                               1
  Chronic pulmonary disease                                                            490--493, 515--518                                               I27.8, I27.9, J40.x--J47.x, J60.x--J67.x, J68.4, J70.1, J70.3                                                                                                                   1
  Rheumatic disease                                                                    712, 716, 734, 446, 139.99                                       M05.x, M06.x, M31.5, M32.x--M34.x, M35.1, M35.3, M36.0                                                                                                                          1
  Peptic ulcer disease                                                                 530.91, 530.98,531--534                                          K25.x--K28.x                                                                                                                                                                    1
  Diabetes without chronic complication                                                249.00, 249.06, 249.07, 249.09, 250.00, 250.06, 250.07, 250.09   E10.0, E10.1, E10.6, E10.8, E10.9, E11.0, E11.1, E11.6, E11.8, E11.9, E12.0, E12.1, E12.6, E12.8, E12.9, E13.0, E13.1, E13.6, E13.8, E13.9, E14.0, E14.1, E14.6, E14.8, E14.9   1
  Diabetes with chronic complication                                                   249.01--249.05, 249.08, 250.01--250.05, 250.08                   E10.2--E10.5, E10.7, E11.2--E11.5, E11.7, E12.2--E12.5, E12.7, E13.2--E13.5, E13.7, E14.2--E14.5, E14.7                                                                         2
  Hemiplegia or paraplegia                                                             344                                                              G04.1, G11.4, G80.1, G80.2, G81.x, G82.x, G83.0--G83.4, G83.9                                                                                                                   2
  Renal disease                                                                        403, 404, 580--584, 590.09, 593.19, 753.10--753.19, 792          I12.0, I13.1, N03.2--N03.7, N05.2--N05.7, N18.x, N19.x, N25.0, Z49.0--Z49.2, Z94.0, Z99.2                                                                                       2
  Any malignancy, including lymphoma and leukemia, except malignant neoplasm of skin   140--15.429, 15.519--194, 200--203, 204--207                     C00.x--C21.x, C23.x--C26.x, C30.x--C34.x, C37.x--C41.x, C43.x, C45.x--C58.x, C60.x--C76.x, C81.x--C85.x, C88.x, C90.x--C97.x                                                    2
  Metastatic solid tumor                                                               195--199                                                         C77.x--C80.x                                                                                                                                                                    6

**Notes:**

AIDS-related diagnoses were not relevant, since patients and controls with HIV/AIDS were excluded. Liver disease-related diagnoses and hepatocellular carcinoma were considered to be part of the causal path between cirrhosis and death, and thus were not included. All ICD-10 codes are according to Quan et al.[@b58-clep-9-501]

**Abbreviation:** ICD-10, 10th revision of the International Statistical Classification of Diseases and Related Health Problems.

###### 

Causes of death

  Cause of death                                                           ICD-10 codes registered in registry of causes of death
  ------------------------------------------------------------------------ --------------------------------------------------------
  Liver-related                                                            Viral hepatitis (B15--B19, B94.2)
  Primary liver cancer (C22.x)                                             
  Alcoholic liver disease (K70.x)                                          
  Other liver diseases (K71--K78)                                          
  Liver-unrelated                                                          Chronic lung diseases (J40--J47)
  Ischemic heart diseases (I20--I25)                                       
  Cerebrovascular diseases (I60--I69)                                      
  Diabetes mellitus (E10--E14)                                             
  Lung cancer (C34.x)                                                      
  Pancreatic cancer (C25.x)                                                
  Non-Hodgkin's lymphoma (C83.x)                                           
  Kidney cancer (C64.x)                                                    
  Colorectal cancer (C18--C20)                                             
  Other cancers (C and D, except for C18--CC20, C22, C25, C34, C64, C83)   
  Alcohol abuse (F10.x)                                                    
  Opioid abuse (F11.x)                                                     
  Other substance abuse (F12--19)                                          
  Other natural causes (all other natural deaths)                          Accidents (X00--X39, X50--X59, V01--V99, W00--W99)
  Suicide (X60--X84)                                                       
  Accidental poisoning (X40--X49)                                          
  Assault (X85--X99, Y00--Y09)                                             
  Injuries (S00--S99, T00--T35, T90--T98)                                  
  Poisoning (T36--T50)                                                     
  Other unnatural causes (T51--T89, Y10--Y98)                              

**Abbreviation:** ICD-10, 10th revision of the International Statistical Classification of Diseases and Related Health Problems.

###### 

Characteristics of patients with SVR and non-SVR at their first EOT~24~ date or baseline, whichever occurred last

  Patient characteristics                                                  SVR             Non-SVR         *P*-value
  ------------------------------------------------------------------------ --------------- --------------- -------------
  n                                                                        233             276             
  Age (median years, range)                                                51.3 (29--75)   53.9 (28--80)   *P*=0.0001
  Sex, n (%)                                                                                               
   Male                                                                    148 (63.5)      189 (68.5)      *P*=0.2
  CCI score, median (range)[a](#tfn19-clep-9-501){ref-type="table-fn"}     0 (0--6)        0 (0--6)        *P*=0.2
   0, n (%)                                                                148 (63.5)      161 (58.3)      
   1--2, n (%)                                                             74 (31.8)       99 (35.9)       
   3--5, n (%)                                                             10 (4.3)        15 (5.4)        
   ≥6, n (%)                                                               1 (0.4)         1 (0.4)         
  Psychiatric disease, n (%)                                               43 (18.5)       47 (17)         *P*=0.67
  Diabetes mellitus, n (%)                                                 29 (12.5)       40 (14.5)       *P*=0.5
  Continent of birth, n (%)                                                                                
   Europe[b](#tfn20-clep-9-501){ref-type="table-fn"}                       176 (75.5)      227 (82.3)      *P*=0.02
   Africa                                                                  6 (2.6)         17 (6.2)        
   Asia                                                                    41 (17.6)       28 (10.1)       
   Other                                                                   4 (1.7)         2 (0.7)         
   Unknown                                                                 6 (2.6)         2 (0.7)         
  Route of transmission, n (%)                                                                             *P*=0.6
   IDU                                                                     109 (46.8)      138 (50.0)      
   Tattoo/piercing                                                         8 (3.4)         8 (2.9)         
   Vertical                                                                0               2 (0.7)         
   Sexual transmission                                                     4 (1.7)         2 (0.7)         
   Blood/blood-product exposure                                            14 (6)          22 (8)          
   Needle injury                                                           1 (0.4)         1 (0.4)         
   Multiple                                                                2 (0.9)         3 (1.1)         
   Other reason                                                            5 (2.2)         2 (0.7)         
   Unknown                                                                 90 (38.6)       98 (35.5)       
  Diagnostic basis for cirrhosis, n (%)                                                                    *P*=0.15
   Liver biopsy                                                            164 (70.4)      185 (67)        
   Clinical cirrhosis                                                      35 (15.0)       59 (21.4)       
   Transient elastography                                                  34 (14.6)       32 (11.6)       
  Decompensated cirrhosis, n (%)                                           19 (8.2)        33 (12)         *P*=0.16
  Hepatocellular carcinoma, n (%)                                          5 (2.2)         14 (5.1)        *P*=0.08
  HCV genotypes, n (%)                                                                                     
   1[c](#tfn21-clep-9-501){ref-type="table-fn"}                            77 (33.1)       144 (52.2)      *P*\<0.0002
   2                                                                       20 (8.6)        9 (3.3)         
   3                                                                       107 (45.6)      99 (35.9)       
   4--6                                                                    5 (2.2)         11 (4)          
   Unknown                                                                 24 (10.3)       13 (4.7)        
  ALT, IU/L, median, IQR (n=502)                                           43 (27--105)    86 (52--139)    *P*\<0.0001
  Alcohol overuse ever,[d](#tfn22-clep-9-501){ref-type="table-fn"} n (%)   94 (40.3)       135 (48.9)      *P*=0.05
  IDU ever,[d](#tfn22-clep-9-501){ref-type="table-fn"} n (%)               113 (48.5)      149 (54)        *P*=0.22

**Notes:**

All patients with no known CCI score at the first EOT24-date or baseline, whichever occurred last, were set to have a CCI score of 0;

Greenland is part of Denmark;

three patients had genotypes 1 and 2 and nine patients had genotypes 1 and 3;

number overall and percentages of patients with IDU/alcohol overuse before end of follow-up.

**Abbreviations:** SVR, sustained virologic response; EOT~24~, 24 weeks after end of treatment; HCV, hepatitis C virus; IDU, intravenous drug use; CCI, Charlson comorbidity index; IQR, interquartile range.

###### 

Cumulative incidences for liver-related morbidity among all patients at risk after SVR, after non-SVR, and among untreated patients, with death and LTx as competing risks

  Morbidity                 All patients, % (95% CI)   After SVR, % (95% CI)   After non-SVR, % (95% CI)   Untreated time, % (95% CI)
  ------------------------- -------------------------- ----------------------- --------------------------- ----------------------------
  HCC, 1-year               1.35 (0.62--2.08)          0.48 (0--1.41)          2.55 (0.68--4.42)           1.28 (0.33--2.23)
  HCC, 5-year               9.14 (7.08--11.2)          5.38 (1.87--8.88)       13.25 (8.65--17.85)         9.79 (6.45--13.12)
  HCC, 10-year              18.3 (14.88--21.71)        6.38 (2.39--10.37)      26.16 (18.7--33.62)         18.99 (13.19--24.8)
  Decompensation, 1-year    5.2 (3.65--6.76)           1.50 (0--3.19)          3.91 (1.53--6.29)           7.57 (4.95--10.19)
  Decompensation, 5-year    15.79 (13--18.6)           5.58 (1.95--9.21)       19.25 (13.67--24.84)        20.86 (15.65--26.07)
  Decompensation, 10-year   28.23 (23.97--32.48)       6.64 (2.5--10.79)       34.69 (26.5--42.89)         36.12 (27.9--44.34)

**Note:** Death and LTx were treated as competing risks.

**Abbreviations:** SVR, sustained virologic response (24 weeks after end of treatment); LTx, liver transplantation; HCC, hepatocellular carcinoma.
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###### 

Baseline characteristics of CHC patients with cirrhosis, and subgroups of untreated patients and patients who initiated treatment before the end of follow-up

  Baseline characteristics                                           All patients    Untreated       Treated         *P*-value[a](#tfn1-clep-9-501){ref-type="table-fn"}
  ------------------------------------------------------------------ --------------- --------------- --------------- -----------------------------------------------------
  n                                                                  1,038           501             537             
  Age (median years, range)                                          51.9 (26--86)   52.2 (26--86)   51.7 (28--80)   *P*=0.11
  Male, n (%)                                                        716 (69)        358 (71.5)      358 (66.7)      *P*=0.1
  CCI, median (range)[b](#tfn2-clep-9-501){ref-type="table-fn"}      0 (0--10)       0 (0--10)       0 (0--6)        *P*\<0.0001
  0, n (%)                                                           632 (60.9)      278 (55.5)      354 (65.9)      
  1--2, n (%)                                                        321 (30.9)      164 (32.7)      157 (29.2)      
  3--5, n (%)                                                        76 (7.3)        52 (10.4)       24 (4.5)        
  ≥6, n (%)                                                          9 (0.9)         7 (1.4)         2 (0.4)         
  Psychiatric disease, n (%)                                         207 (19.9)      123 (24.6)      84 (15.6)       *P*=0.0003
  Diabetes mellitus, n (%)                                           127 (12.2)      71 (14.2)       56 (10.4)       *P*=0.07
  Continent of birth, n (%)                                                                                          *P*=0.003
   Europec                                                           861 (83)        434 (86.6)      427 (79.5)      
   Africa                                                            41 (4)          18 (3.6)        23 (4.3)        
   Asia                                                              105 (10.1)      32 (6.4)        73 (13.6)       
   Other                                                             14 (1.4)        8 (1.6)         6 (1.1)         
   Unknown                                                           17 (1.6)        9 (1.8)         8 (1.5)         
  Transmission, n (%)                                                                                                *P*=0.07
   IDU                                                               559 (53.9)      303 (60.5)      256 (47.7)      
   Tattoo/piercing                                                   31 (3)          12 (2.4)        19 (3.5)        
   Vertical                                                          6 (0.6)         4 (0.8)         2 (0.4)         
   Sexual transmission                                               13 (1.3)        6 (1.2)         7 (1.3)         
   Blood/blood product                                               70 (6.7)        32 (6.4)        38 (7.1)        
   Needle injury                                                     12 (1.2)        10 (2)          2 (0.4)         
   Multiple                                                          8 (0.8)         3 (0.6)         5 (0.9)         
   Other reason                                                      11 (1.1)        3 (0.6)         8 (1.5)         
   Unknown                                                           328 (31.6)      128 (25.6)      200 (37.2)      
  Diagnostic method, n (%)                                                                                           *P*\<0.0001
   Liver biopsy                                                      491 (47.3)      132 (26.4)      359 (66.9)      
   Clinical cirrhosis                                                384 (37)        279 (55.7)      105 (19.6)      
   Transient elastography                                            163 (15.7)      90 (18)         73 (13.6)       
  Decompensation, n (%)                                              224 (21.6)      174 (37.7)      50 (9.3)        *P*\<0.0001
   HCC, n (%)                                                        42 (4)          28 (5.6)        14 (2.6)        *P*=0.01
   HCV genotype 1,[d](#tfn4-clep-9-501){ref-type="table-fn"} n (%)   443 (42.7)      210 (42)        233 (43.4)      *P*=0.36
   HCV genotype 2                                                    63 (6.1)        32 (6.4)        31 (5.6)        
   HCV genotype 3                                                    378 (36.4)      159 (31.7)      219 (40.8)      
   HCV genotype 4--6                                                 28 (2.7)        12 (2.4)        16 (3)          
   Unknown genotype                                                  126 (12.1)      88 (17.6)       38 (7.1)        
  ALT, IU/L, median, IQR                                             83 (48--136)    69 (41--116)    95 (57--152)    *P*\<0.0001
  Alcohol overuse,[e](#tfn5-clep-9-501){ref-type="table-fn"} n (%)   591 (56.9)      353 (70.5)      238 (44.3)      *P*\<0.0001
  IDU,[e](#tfn5-clep-9-501){ref-type="table-fn"} n (%)               595 (57.3)      323 (64.5)      272 (50.7)      *P*\<0.0001

**Notes:**

Patients who initiated treatment prior to end of follow-up vs untreated patients;

all patients with no known CCI score at baseline were set to have a CCI score of 0;

Greenland is part of Denmark;

three patients had genotypes 1 and 2, nine patients had genotypes 1 and 3, and one patient had genotype 1 and 4;

number overall and percentage of patients with IDU/alcohol overuse before end of follow-up.

**Abbreviations:** CHC, chronic hepatitis C; CCI, Charlson comorbidity index; HCC, hepatocellular carcinoma; IDU, intravenous drug use HCV, hepatitis C virus; IQR, interquartile range.

###### 

Liver-related morbidity and mortality incidence rates for patients with chronic hepatitis C and for patients with SVR, non-SVR and for untreated patients

  Morbidity and mortality rates    All patients (95% CI)       SVR (95% CI)                Non-SVR (95% CI)            Untreated (95% CI)
  -------------------------------- --------------------------- --------------------------- --------------------------- ------------------------------
  All-cause MR                     7.33/100 PYs (6.41--8.39)   2.17/100 PYs (1.4--3.38)    6.64/100 PYs (5.28--8.36)   12.12/100 PYs (10.29--14.35)
  Liver-related MR                 4.38/100 PYs (3.36--5.7)    1/100 PYs (0.58--1.74)      3.87/100 PYs (3.01--4.96)   7.49/100 PYs (5.79--9.69)
  HCC IR                           2.49/100 PYs (2.12--2.94)   0.85/100 PYs (0.52--1.41)   3.53/100 PYs (2.80--4.45)   2.79/100 PYs (2.17--3.6)
  HCC IR with alcohol overuse      3.25/100 PYs (2.65--3.98)   1.36/100 PYs (0.67--2.77)   4.73/100 PYs (3.54--6.32)   2.99/100 PYs (2.21--4.03)
  HCC IR without alcohol overuse   1.76/100 PYs (1.34--2.31)   0.62/100 PYs (0.35--1.11)   2.51/100 PYs (1.74--3.63)   2.41/100 PYs (1.51--3.84)
  Decompensation IR                3.9/100 PYs (3.32--4.59)    1/100 PYs (0.6--1.65)       4.53/100 PYs (3.63--5.66)   6.08/100 PYs (4.86--7.61)

**Abbreviations:** SVR, sustained virologic response (24 weeks after end of treatment); MR, mortality rate; PYs, person-years; HCC, hepatocellular carcinoma; IR, incidence rate.

###### 

Adjusted liver-related morbidity IRRs among all patients with chronic hepatitis C and cirrhosis

  Adjusted morbidity rate ratios                                                                                             IRR (95% CI)
  -------------------------------------------------------------------------------------------------------------------------- -------------------
  HCC IRR,[a](#tfn8-clep-9-501){ref-type="table-fn"} male vs female                                                          1.21 (0.86--1.69)
  HCC IRR,[a](#tfn8-clep-9-501){ref-type="table-fn"} diabetes                                                                1.29 (0.89--1.88)
  HCC IRR,[a](#tfn8-clep-9-501){ref-type="table-fn"} alcohol overuse                                                         1.78 (1.29--2.46)
  HCC IRR,[a](#tfn8-clep-9-501){ref-type="table-fn"} genotype[b](#tfn9-clep-9-501){ref-type="table-fn"} 2 vs 1               0.61 (0.28--1.34)
  HCC IRR,[a](#tfn8-clep-9-501){ref-type="table-fn"} genotype[b](#tfn9-clep-9-501){ref-type="table-fn"} 3 vs 1               1.61 (1.16--2.22)
  HCC IRR,[a](#tfn8-clep-9-501){ref-type="table-fn"} genotype[b](#tfn9-clep-9-501){ref-type="table-fn"} 3 vs 2               2.65 (1.20--5.82)
  Decompensation IRR,[a](#tfn8-clep-9-501){ref-type="table-fn"} male vs female                                               1.29 (0.86--1.93)
  Decompensation IRR,[a](#tfn8-clep-9-501){ref-type="table-fn"} diabetes                                                     1.65 (1.09--2.48)
  Decompensation IRR,[a](#tfn8-clep-9-501){ref-type="table-fn"} alcohol overuse                                              2.16 (1.51--3.15)
  Decompensation IRR,[a](#tfn8-clep-9-501){ref-type="table-fn"} genotype[c](#tfn10-clep-9-501){ref-type="table-fn"} 2 vs 1   0.96 (0.48--1.94)
  Decompensation IRR,[a](#tfn8-clep-9-501){ref-type="table-fn"} genotype[c](#tfn10-clep-9-501){ref-type="table-fn"} 3 vs 1   0.91 (0.63--1.33)
  Decompensation IRR,[a](#tfn8-clep-9-501){ref-type="table-fn"} genotype[c](#tfn10-clep-9-501){ref-type="table-fn"} 3 vs 2   0.95 (0.46--1.95)

**Notes:**

Adjusted for age, sex, genotype (1, 2, 3, 4--6, multiple), alcohol overuse, and diabetes as appropriate;

type 3 test, *P*=0.0074 for genotype, *df*=4;

type 3 test, *P*=0.94, *df*=4.

**Abbreviations:** IRR, incidence rate ratio; HCC, hepatocellular carcinoma.

###### 

Adjusted liver-related morbidity and MRRs for patients with SVR vs non-SVR

  Adjusted morbidity and mortality rate ratios                                                           SVR (95% CI)         Non-SVR (95% CI)
  ------------------------------------------------------------------------------------------------------ -------------------- -------------------
  All-cause MRR,[a](#tfn12-clep-9-501){ref-type="table-fn"} SVR vs non-SVR                               0.68 (0.43--1.09)    
  Liver-related MRR,[a](#tfn12-clep-9-501){ref-type="table-fn"} SVR vs non-SVR                           0.6 (0.36--1)        
  HCC IRR,[b](#tfn13-clep-9-501){ref-type="table-fn"} SVR vs non-SVR                                     0.35 (0.21--0.6)     
  HCC IRR,[b](#tfn13-clep-9-501){ref-type="table-fn"} diabetes vs non-diabetes                           1.14 (0.36--3.61)    1.23 (0.7--2.14)
  HCC IRR,[b](#tfn13-clep-9-501){ref-type="table-fn"} male vs female                                     1.90 (0.6--5.97)     1.5 (0.89--2.53)
  HCC IRR,[b](#tfn13-clep-9-501){ref-type="table-fn"} alcohol overuse vs no alcohol overuse              1.77 (0.67--4.67)    1.51 (0.97--2.36)
  Decompensation IRR,[b](#tfn13-clep-9-501){ref-type="table-fn"} SVR vs non-SVR                          0.31 (0.17--0.57)    
  Decompensation IRR,[b](#tfn13-clep-9-501){ref-type="table-fn"} alcohol overuse vs no alcohol overuse   3.38 (1.11--10.28)   1.97 (1.2--3.23)
  Decompensation IRR,[b](#tfn13-clep-9-501){ref-type="table-fn"} diabetes vs no diabetes                 1.38 (0.35--5.39)    2.07 (1.18--3.63)
  Decompensation IRR,[b](#tfn13-clep-9-501){ref-type="table-fn"} male vs female                          1.88 (0.48--7.31)    0.95 (0.56--1.61)

**Notes:**

Adjusted for age, sex, alcohol overuse, intravenous drug use, HCC, decompensation, Charlson comorbidity index score, psychiatric disease, and liver transplantation;

adjusted for sex, age, alcohol overuse, diabetes, HCV genotype (1, 2, 3, 4--6. and multiple genotypes), and SVR as appropriate.

**Abbreviations:** MRRs, mortality rate ratios; SVR, sustained virologic response (24 weeks after end of treatment); HCC, hepatocellular carcinoma; IRR, incidence rate ratio; HCV, hepatitis C virus.
